NCT02419287
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- ASST-Monza Monza, Italy/MB, Italy
Clinical trial condition
Anaplastic Large Cell Lymphoma, ALK-Positive
Explore clinical trials studying Anaplastic Large Cell Lymphoma, ALK-Positive. Study availability and eligibility vary by location and protocol.
13 public trials
4 recruiting studies
Anaplastic Large Cell Lymphoma, ALK-Positive trial results
Active, Not Recruiting
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978625
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
Active, Not Recruiting
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- M D Anderson Cancer Center Houston, Texas, United States